WO2026112141 - THERAPEUTIC METHODS AND USES FOR ANTIBODIES TO HUMAN MASP-3
National phase entry is expected:
Publication Number
WO/2026/112141
Publication Date
28.05.2026
International Application No.
PCT/US2025/056111
International Filing Date
19.11.2025
Title **
[English]
THERAPEUTIC METHODS AND USES FOR ANTIBODIES TO HUMAN MASP-3
[French]
MÉTHODES THÉRAPEUTIQUES ET UTILISATIONS D'ANTICORPS DIRIGÉS CONTRE MASP-3 HUMAINE
Applicants **
NOVO NORDISK HEALTH CARE AG
Inventors
CUMMINGS, William Jason
PULLMAN, William
WHITAKER, John Steven
Priority Data
63/723,450
21.11.2024
US
63/727,826
04.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3275 | |
| EPO | Filing, Examination, Granting | 25368 | |
| Japan | Filing, Examination, Granting | 2896 | |
| South Korea | Filing, Examination, Granting | 3766 | |
| USA | Filing, Examination, Granting | 8110 |
Total:
43,415
Contact Us
Abstract[English]
Methods of treating paroxysmal nocturnal hemoglobinuria using MASP-3 serine protease inhibitors are provided. In some embodiments, the MASP-3 serine protease inhibitors are anti-MASP-3 antibodies. Also provided are uses of MASP-3 serine protease inhibitors in treatment of paroxysmal nocturnal hemoglobinuria, and for manufacture of a medicament for treatment of paroxysmal nocturnal hemoglobinuria.[French]
L'invention concerne des méthodes de traitement d'hémoglobinurie paroxystique nocturne à l'aide d'inhibiteurs de sérine protéase MASP-3. Dans certains modes de réalisation, les inhibiteurs de la sérine protéase MASP-3 sont des anticorps anti-MASP-3. L'invention concerne également des utilisations d'inhibiteurs de sérine protéase MASP-3 dans le traitement de l'hémoglobinurie paroxystique nocturne, et pour la fabrication d'un médicament pour le traitement de l'hémoglobinurie paroxystique nocturne.